Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

Moderna stock surged Thursday after the Covid vaccine-maker significantly cut its third-quarter costs, and still managed to ...

Moderna beat analysts’ revenue expectations by 10.7% last quarter, reporting revenues of $142 million, down 41.1% year on year. It was a satisfactory quarter for the company, with a beat of analysts’ ...

Moderna’s nearly $20 billion cash hoard has dwindled to a single-digit stash. Following a series of setbacks for the biotech, ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

Berenberg lowered the firm’s price target on Moderna (MRNA) to $28 from $30 and keeps a Hold rating on the shares. The firm thinks BioNTech’s ...

The company posted a net loss of 51 cents a share, against Wall Street’s expectation for a loss of $2.21. Moderna has ...

Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ:MRNA) ...

As you might know, Moderna, Inc. (NASDAQ:MRNA) just kicked off its latest quarterly results with some very strong numbers.

For the quarter ended September 2025, Moderna (MRNA) reported revenue of $1.02 billion, down 45.4% over the same period last ...

July 31 (Reuters) - Moderna (MRNA.O), opens new tab said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of the year, as the biotech ...